

If you have Polycystic Kidney Disease you may qualify for a clinical study



FALCON is a Phase 3 clinical study evaluating the effectiveness and safety of bardoxolone methyl (an oral investigational drug) in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).



You may be eligible for this study if you:

- Are 12 to 70 years of age
- Have been diagnosed with ADPKD

Other eligibility criteria will apply.

www.PKDstudy.com

This study is being sponsored by Reata Pharmaceuticals, Inc. www.clinicaltrials.gov (NCT03918447) ENG V2.0 file dated Apr2022
US-NNP-2200013 09/2022